BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

Core Insights - BioRestorative Therapies, Inc. has appointed Francisco Silva as the Section Editor for the newly launched Regenerative Medicine section of the Journal of Translational Medicine, highlighting the company's commitment to advancing research in regenerative medicine [2][15]. Company Overview - BioRestorative Therapies, Inc. is a clinical-stage company focused on developing stem cell-based therapies, particularly targeting musculoskeletal and metabolic disorders [15][17]. - The company operates two core clinical development programs: the Disc/Spine Program (brtxDISC™) and the Metabolic Program (ThermoStem®), along with a commercial BioCosmeceutical platform [5][11][17]. Research and Development - Francisco Silva has extensive experience in developing cell-based therapeutics and is currently leading a Phase 2 study for BRTX-100, aimed at treating chronic lumbar disc disease [9][11]. - The Metabolic Program utilizes brown adipose derived stem cells (BADSC) to develop therapies targeting obesity and metabolic disorders, with initial preclinical research indicating potential benefits in caloric burning and metabolic regulation [5][12]. Product Offerings - The BRTX-100 product is formulated from autologous cultured mesenchymal stem cells and is intended for non-surgical treatment of painful lumbosacral disc disorders [11]. - The BioCosmeceutical platform includes a proprietary biologic serum designed to reduce fine lines and wrinkles, with plans to expand the product line through FDA approvals [6][17]. Journal Impact - The Journal of Translational Medicine, where the new section will be featured, has a 2021 impact factor of 8.440, ranking it among the top 3% of journals globally, indicating a strong platform for disseminating research in regenerative medicine [8].